The US Food and Drug Administration (FDA) has approved fitusiran (Qfitlia, Sanofi) for bleeding prophylaxis in patients aged 12 years or older with hemophilia A and B with or without factor VIII ...

Fitusiran is an anti-thrombin-directed small interfering ribonucleic acid therapeutic that prevents bleeds in patients with hemophilia A or B by reducing antithrombin levels. The efficacy and ...

The drug fitusiran, which will go by the brand name Qfitlia, is the first new treatment for both types of hemophilia — A and B. It can also be given to both patients who have antibodies that ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Qfitlia contains fitusiran, which uses RNA interference (RNAi) to block the production of AT, providing effective treatment for hemophilia, even in patients with inhibitors. It is given as a shot ...

M.D., Sanofi’s hemophilia program leader, said in an interview with Fierce Pharma. “We’re obviously excited about fitusiran because it’s the first therapy in the United States that can be ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi). Fitusiran (Qfitlia ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent ...

Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or ... approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered ...

Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages 12 years and up with hemophilia A or B ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.